Skip to content
Back to explorer
Printable monograph

Antifolate

Methotrexate (high-dose)

Trexall · HD-MTX

Antifolate · approved 1953 · 10 citations · FAERS AKI reporting ROR 1.07 (95% CI 1.04–1.10, 5,575 AKI reports)

Up to date· through 2025
Deeply sourced8/9 · 7 signals
  • Met: 10 citations
  • Not met: 12+ references
  • Met: Accrued over 10+ years (span: 15y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2025
  • Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

The crystal-former — precipitates in acidic urine and clogs the tubule.

ModerateAntifolate antimetabolite
OsteosarcomaALLCNS lymphoma

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Avoid or contraindicated in impairment
High-dose MTX contraindicated or sharply dose-reduced when CrCl/eGFR low; withhold until prior AKI resolves; titrate leucovorin to MTX levels
The atlas summary, paraphrased — not label text. Verbatim label excerpt. Dosing section.
Hemodialysis
Partly removed by hemodialysis
Use restricted: High-dose MTX contraindicated or sharply dose-reduced at low CrCl and withheld until prior AKI resolves.
Intermittent HD clears MTX inefficiently with post-dialysis rebound, so glucarpidase (not dialysis) is the definitive rescue for MTX-induced AKI with toxic levels.PMID 29079637 (opens PubMed in a new tab)
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: JYLAMVO, Nov 2026. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

Representative incidence7%

2–12% range across studies

AKI in ~2–12% of patients and 2–39% of high-dose courses, with severe (AKIN grade ≥2) nephrotoxicity in ~2% of courses.Source: Howard et al., Oncologist 2016; Kala & Howard, Am J Nephrol 2025

Onset & rechallenge

Time to injuryAcute (~1–7 days)

AKI within hours to days of infusion.

Distilled from: “Acute — within hours to days of infusion.”

RechallengeOften tolerated

High-dose methotrexate has been safely resumed after AKI and glucarpidase rescue in a pediatric series. PMID 22252903 (opens PubMed in a new tab)

Long-term outlook & early detection

Renal recovery

Usually reversible

HD-MTX crystal nephropathy is characteristically an acute, reversible AKI: once toxic exposure is cleared with intensified hydration/urinary alkalinization, high-dose leucovorin, and glucarpidase, renal function typically recovers, and HD-MTX can often be safely resumed after recovery. The injury is self-amplifying (reduced clearance raises MTX exposure), so prompt rescue is what determines the reversible course.PMID 20679598 (opens PubMed in a new tab)

Early-detection biomarkers

  • Serial plasma methotrexate concentration (24/48/72 h post-infusion) — Delayed methotrexate clearance / impending crystal-nephropathy AKI. The drug's own monitoring backbone and earliest signal: a rising or plateauing MTX level (vs the ~0.05-0.1 micromol/L clearance threshold) flags nephrotoxicity and delayed elimination before or alongside a creatinine rise, and drives leucovorin escalation and glucarpidase-rescue thresholds. After glucarpidase, avoid immunoassay: DAMPA cross-reacts and falsely elevates the reading, for about 48 h per this consensus but for 5 days in a published case (Young et al., PMID 31903191).PMID 29079637 (opens PubMed in a new tab)
  • Urinary KIM-1 and NGAL — Proximal tubular injury. Studied in 86 childhood acute lymphoblastic leukemia (ALL) survivors a median 6.6 years after treatment ended: median creatinine-indexed urinary KIM-1 and NGAL were higher than in 53 healthy peers, consistent with subclinical tubular damage — but neither cumulative methotrexate nor cumulative cyclophosphamide dose predicted the markers, so this is survivor-cohort evidence of late tubular injury after multi-agent therapy rather than a methotrexate-specific signal. Research-grade rather than a validated clinical trigger.PMID 33052454 (opens PubMed in a new tab)
  • Serum cystatin C (and urinary KIM-1/clusterin) — Early glomerular filtration decline, less confounded by muscle mass than creatinine. Evaluated prospectively as early kidney-injury markers around each HD-MTX dose. Honest caveat: in this pediatric HDMTX cohort the biomarker panel (cystatin C, KIM-1, clusterin, FGF23) did not identify kidney injury more frequently than serum creatinine alone, so cystatin C remains investigational here rather than an established replacement for creatinine-based monitoring.PMID 40549937 (opens PubMed in a new tab)

Distilled from the agent's cited literature — educational, not a substitute for the primary sources.

Recovery across agents

Host risk modifiers

Germline / pharmacogenomic variants that shift an individual's risk of this agent's kidney injury. Research-grade — not routine clinical testing.

  • MTHFRc.677C>T (rs1801133, Ala222Val)

    T allele raises risk of high-dose methotrexate renal toxicity (meta-analysis: recessive OR 3.54, 95% CI 1.81-6.90; allelic OR 1.89, 95% CI 1.18-3.02); reduced MTHFR activity is thought to potentiate MTX antifolate/tubular injury PMID 34744734 (opens PubMed in a new tab)

  • SLCO1B1rs11045879 (intronic; LD with reduced-function c.521T>C/rs4149056)

    Low-clearance genotype slows OATP1B1-mediated MTX elimination (genome-wide significant, meta-analysis P=3.13x10^-19), prolonging high plasma MTX exposure - the principal driver of HD-MTX crystal/tubular nephrotoxicity; carriers warrant closer level monitoring and hydration/leucovorin PMID 23233662 (opens PubMed in a new tab)

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Grade >=2 HDMTX nephrotoxicity in 68 of 3,887 (1.8%) osteosarcoma patients treated on clinical protocols; 4.4% of those 68 died. Crystalline precipitation of MTX and 7-OH-MTX in the acidic tubular lumen is the dominant mechanism.

    Not the same figure as §01's 7%. §01 is AKI of any severity across high-dose methotrexate studies; this row is grade 2 or worse nephrotoxicity in 3,887 osteosarcoma patients treated on clinical trials.

  2. Acute Tubular NecrosisSecondaryqualitative — no citable incidence

    Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

7%incidence

Representative incidence · 2–12% range across studies

SeverityModerate
ReversibilityReversible
Evidence10 citations
Nephron map

Crystal / Obstructive Nephropathy strikes: Tubular Lumen.

Proximal Tubule — not involved
Distal Tubule / Collecting Duct — not involved
Tubular Lumen — struck by Crystal / Obstructive NephropathyThe urine flow path

Crystal / Obstructive Nephropathy

Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.

§03

Kidney injury

Deep diveHigh-dose methotrexate crystal nephropathyHigh-dose methotrexate is cleared by the kidney, so when it and its poorly-soluble metabolite crystallize in the acidic tubular lumen the kidney injures itself — and because that same kidney is what clears the drug, injury feeds a spiral of rising levels that leucovorin cannot break but an enzyme can.Appears in 1 documented synergy combination

Mechanism of kidney injury

Methotrexate and its 7-OH metabolite are poorly soluble in acidic urine and precipitate as intratubular crystals, causing obstruction plus direct tubular toxicity. The resulting AKI impairs methotrexate clearance, spiraling into systemic toxicity.

Clinical presentation

Non-oliguric AKI, rising creatinine, markedly delayed methotrexate clearance and crystalluria.

Management

Intensify hydration and alkalinization, increase leucovorin, and give glucarpidase (cleaves plasma MTX) for severe AKI. Hemodialysis is relatively ineffective.Lesion-level management framework

Risk factors

  • Volume depletion
  • Acidic urine
  • Third-spacing (ascites/effusions)
  • Interacting drugs (NSAIDs, PPIs, penicillins)

Prevention

  • Aggressive hydration
  • Urinary alkalinization to pH > 7
  • Leucovorin rescue
  • Avoid interacting drugs
Anticancer mechanism· how it treats cancer

Inhibits dihydrofolate reductase, blocking purine and thymidylate synthesis. High-dose protocols treat osteosarcoma, ALL and CNS lymphoma.

§04

Clinical depth

Renal dose adjustment

High-dose MTX (>500 mg/m2) is predominantly renally cleared, so it is contraindicated or sharply dose-reduced when CrCl/eGFR is low and is generally withheld until any prior AKI resolves; nephrotoxicity itself is the chief driver of toxic exposure because delayed clearance prolongs systemic MTX and amplifies marrow/mucosal/hepatic toxicity. Rather than a single fixed CrCl band, practice is to confirm adequate baseline renal function, intensify hydration and urinary alkalinization, and titrate leucovorin rescue against serial MTX levels (Bleyer-type nomogram).

Dialyzability & ESKD dosing

Conventional intermittent hemodialysis clears MTX inefficiently and is followed by substantial post-dialysis rebound from tissue redistribution, so it is not a reliable rescue for MTX overexposure; high-flux/high-efficiency HD and continuous modalities (CVVHD) remove somewhat more but still lag far behind enzymatic clearance. Glucarpidase (carboxypeptidase-G2), which cleaves circulating MTX to inactive metabolites within minutes, is the definitive intervention for MTX-induced AKI with toxic levels and largely supplants dialysis.

Differential diagnosis

MTX crystal nephropathy is suggested by AKI arising during or shortly after a HD-MTX infusion together with a rising/plateauing MTX level (delayed clearance), often a relatively bland urinalysis, and an acidic, low-volume urine - distinct from prerenal azotemia (low FeNa, volume-responsive) and from other tubular toxins. Concurrent tumor lysis (uric acid crystals) and contrast or aminoglycoside ATN are the main mimics; the temporal link to MTX dosing and the elevated drug level point to MTX as the culprit.

Monitoring

  • Serial plasma MTX concentrations at scheduled intervals (e.g., 24/48/72 h post-infusion) until below the clearance threshold (~0.05-0.1 micromol/L); a rising or plateauing level signals nephrotoxicity and impending delayed clearance.
  • Serum creatinine/eGFR daily during and after the infusion; a creatinine rise is an early sign of crystal nephropathy and should trigger leucovorin escalation.
  • Urine pH with every void or bag during HD-MTX, targeting pH >=7.0 to keep MTX and 7-OH-MTX soluble; adjust IV sodium bicarbonate to maintain it.
  • Strict intake/output and body weight to confirm high urine flow and avoid volume depletion that promotes tubular crystal precipitation.
  • Review concomitant drugs that delay MTX clearance or displace it (NSAIDs, penicillins, probenecid, PPIs, sulfonamides) and hold them around dosing.

Key trials & series

  • Ramsey et al., Oncologist 2018 - consensus guideline on monitoring, prevention, and management of HD-MTX-induced nephrotoxicity, codifying aggressive hydration/alkalinization, the leucovorin nomogram, and glucarpidase use.
  • Widemann et al., expanded-access/compassionate-use glucarpidase series - rapid (>97%) reduction in plasma MTX and renal recovery in MTX-induced AKI, supporting glucarpidase (Voraxaze) approval.
  • Howard et al., Oncologist 2016 ('Preventing and Managing Toxicities of High-Dose Methotrexate') - clinical-review framework for risk stratification, supportive measures, and glucarpidase indications.

Clinical pearls

  • The lesion is largely a crystal nephropathy: poorly soluble MTX and its metabolite 7-OH-MTX precipitate in acidic distal tubules, so prophylaxis hinges on high urine flow plus alkalinization to pH >=7.0 - solubility of MTX rises several-fold between pH 6 and 7.
  • Nephrotoxicity is self-amplifying: reduced clearance raises MTX exposure, which worsens marrow, mucosal, hepatic, and renal injury - hence the urgency of serial levels and prompt rescue.
  • Leucovorin rescues normal tissues but does NOT lower the MTX level; for genuine AKI with toxic concentrations, glucarpidase is the agent that actually reduces drug burden, and leucovorin must be continued (and timed apart from glucarpidase, which also degrades leucovorin).
  • Avoid measuring MTX by immunoassay after glucarpidase: DAMPA, an inactive cleavage product, cross-reacts and falsely elevates the reported level - for about 48 h per the consensus guideline (Ramsey et al., PMID 29079637), but for 5 days in a published case (Young et al., PMID 31903191); use chromatographic assays.
Beyond the kidney — non-renal toxicities· 4 organ systems

Class-level context for the major non-renal toxicities of the Antifolate class.

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

  • Mucositis and diarrhea

Hepatic / Liver

Transaminitis, hepatitis, VOD/SOS

  • Transaminitis (methotrexate)

Hematologic

Cytopenias, thrombosis, TMA

  • Myelosuppression

Pulmonary

Pneumonitis, ILD, effusions, hypertension

  • Methotrexate / gemcitabine pneumonitis
§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2010–2025 · 3 since 2023
202010: 1 citation2012: 1 citation2016: 1 citation2018: 1 citation2023: 1 citation2025: 2 citations201020202025

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.High-Dose Methotrexate Nephrotoxicity.Kala J, Howard SC · Am J Nephrol · 2025 · PMID 41134727Narrative review synthesizing HDMTX (>500 mg/m2) nephrotoxicity: AKI in 2-39% of courses, severe AKIN grade >=2 in ~2%, plus MTX pharmacokinetics/pharmacodynamics, pathophysiology of renal injury, and prevention/management pathway (increased hydration, high-dose leucovorin, glucarpidase).
  2. 2.Methotrexate nephrotoxicity: a pragmatic approach.Mouawad Y, Kala J · Curr Opin Nephrol Hypertens · 2025 · PMID 41355387Review of HDMTX nephrotoxicity and delayed methotrexate elimination (DME).
  3. 3.LandmarkPreventing and Managing Toxicities of High-Dose Methotrexate.Howard SC et al. · Oncologist · 2016 · PMID 27496039Crystal nephropathy mechanism, 2–12% AKI incidence and prevention.
  4. 4.Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.Ramsey LB et al. · Oncologist · 2018 · PMID 29079637Expert thresholds for glucarpidase rescue.
  5. 5.LandmarkGlucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.Widemann BC et al. · J Clin Oncol · 2010 · PMID 20679598Glucarpidase cuts plasma MTX 98.7% in 15 minutes.
  6. 6.Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.Christensen AM et al. · Cancer · 2012 · PMID 22252903St. Jude series quantifying glucarpidase use and safe rechallenge.
  7. 7.The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity - a review of pharmacological and clinical data.Kielbowski K et al. · Expert Opin Drug Metab Toxicol · 2023 · PMID 37846862Recent review of glucarpidase pharmacology and efficacy.
Conference abstracts & journal reports· 1 non-PubMed
FDA label — boxed warning & renal dosing· boxed warning · renal impairment

Quoted verbatim from this agent's current FDA label (Nov 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS and SEVERE ADVERSE REACTIONS Methotrexate can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Jylamvo is contraindicated in pregnancy. For neoplastic diseases, advise females and males of reproductive potential to use effective contraception during and after treatment with Jylamvo [see Contraindications (4) , Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ] . Jylamvo is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [ Contraindications (4) , Warnings and Precautions (5.2) ] . Serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, gastrointestinal tract, liver, lungs, skin, and kidneys. Withhold or discontinue Jylamvo as appropriate [ Warnings and Precautions (5.3 , 5.4 , 5.5 , 5.6 , 5.7 , 5.8 , 5.9 , 5.11) ] . WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, and SEVERE ADVERSE REACTIONS See full prescribing information for complete boxed warning. Methotrexate can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Jylamvo is contraindicated in pregnancy. For neoplastic diseases, advise patients of reproductive potential of the potential risk to a fetus…

Renal impairment — from the label

Methotrexate elimination is reduced in patients with renal impairment [see Clinical Pharmacology (12.3) ] . Patients with renal impairment are at increased risk for methotrexate adverse reactions. Closely monitor patients with renal impairment [creatinine clearance (CLcr) less than 90 mL/min, Cockcroft-Gault] for adverse reactions. Reduce the dosage or discontinue JYLAMVO as appropriate [see Warnings and Precautions (5.8) ] .

Kidney rows of the label's dosage tables

None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 494,382 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 4 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Crystal / Obstructive Nephropathyreporting signal · ROR 1.97 — on terms merely consistent with the lesion; none names it, so this does not corroborate it
  • Acute Tubular NecrosisNot measurable in reporting — Reporters cannot reliably name this lesion, so its absence from FAERS is expected and is not evidence against the documented injury.
Thrombotic Microangiopathy
ROR 2.5795% CI 2.41–2.74· 1,010 reports· IC025 1.20
Hypertension
ROR 2.1495% CI 2.11–2.17· 19,305 reports· IC025 1.00
Hemorrhagic Cystitis
ROR 2.1395% CI 2.06–2.20· 3,561 reports· IC025 0.99
Crystal / Obstructive Nephropathy
ROR 1.9795% CI 1.90–2.05· 2,645 reports· IC025 0.88
FAERS outcomes & reporting trend· 7.8% of reports w/ death · 27.3% w/ hospitalization
7.8%

Reported with a death outcome

38,386 of 494,382 reports

27.3%

Reported with hospitalization

134,962 of 494,382 reports

Reports per year

  • 2015: 21,417 reports
  • 2016: 25,808 reports
  • 2017: 32,921 reports
  • 2018: 45,090 reports
  • 2019: 41,850 reports
  • 2020: 46,598 reports
  • 2021: 31,330 reports
  • 2022: 35,220 reports
  • 2023: 32,686 reports
  • 2024: 28,168 reports
  • 2025: 23,871 reports
  • 2026: 13,579 reports

Reports received per year, 2015–2026 · most recent year is partial · 115,844 of the 494,382 reports predate 2015 and are not drawn.

FAERS adverse-event signal — all organ systems· 7 systems · 494,382 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 1.0795% CI 1.04–1.10· 5,575 AKI reports· IC025 0.05·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.
Musculoskeletal
Rheumatoid Arthritis43,139Arthralgia41,149Joint Swelling25,192Pain In Extremity20,243Musculoskeletal Stiffness14,923
General / constitutional
Pain40,057Fatigue33,327Pyrexia19,165Malaise17,657Peripheral Swelling15,139
Gastrointestinal
Nausea29,270Diarrhoea21,063Vomiting17,692Abdominal Discomfort16,370
Immune / infection
Drug Hypersensitivity19,759Pneumonia18,485Nasopharyngitis15,729Infection15,419
Skin
Rash22,700Alopecia17,571
Nervous system
Headache23,640
Respiratory
Dyspnoea16,525
Guidelines & consensus· 15

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Methotrexate (high-dose) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Raltitrexed

Tomudex · Antifolate (TS inhibitor)

Profile

Renally cleared antifolate; exposure ~doubles in renal impairment; forerunner CB3717 withdrawn for crystal nephrotoxicity.

ATNXTAL
Moderate#1 · 99% phenotype match

Pralatrexate

Folotyn · Antifolate

Profile

Antifolate with MTX-like renal handling.

XTALATN
Moderate#2 · 89% phenotype match

CAR-T cell therapy

Kymriah · Yescarta · CAR-T cell therapy

Profile

CRS-driven prerenal AKI and tumor lysis.

PREATNXTAL
Moderate#3 · 65% phenotype match

Lurbinectedin

Zepzelca · Marine alkylating agent

Profile

Rhabdomyolysis risk in small-cell lung cancer.

ATNLYTEXTAL
Mild#4 · 65% phenotype match

Clofarabine

Clolar · Purine analog

Profile

Capillary-leak / SIRS-like AKI and tumor lysis.

PREATNGLOM+1 more
Moderate#5 · 59% phenotype match

Blinatumomab

Blincyto · BiTE (CD19×CD3)

Profile

CRS and tumor lysis → AKI.

PREATNXTAL
Moderate#6 · 58% phenotype match
Compare Methotrexate (high-dose) with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Antimetabolites

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1CapecitabineMild
  2. 2CladribineMild
  3. 35-FluorouracilFAERS AKIMild
  4. 4HydroxyureaFAERS AKIMild
  5. 4NelarabineFAERS AKIMild
  6. 6DecitabineFAERS AKIMild
  7. 7Trifluridine/tipiracilModerate
  8. 8PralatrexateModerate
  9. 9Carmofur (HCFU)FAERS n/aModerate
  10. 9DoxifluridineModerate
  11. 11Methotrexate (high-dose)· this agentFAERS AKIModerate
  12. 11RaltitrexedFAERS AKIModerate
  13. 13FludarabineFAERS AKIModerate
  14. 13PentostatinFAERS AKIModerate
  15. 15AzacitidineFAERS AKIModerate
  16. 15ClofarabineFAERS AKIModerate
  17. 15CytarabineFAERS AKIModerate
  18. 15PemetrexedFAERS AKIModerate
  19. 19Tegafur-uracil (UFT)Severe
  20. 20GemcitabineFAERS AKISevere

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Methotrexate (high-dose)’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Methotrexate (high-dose); the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

  1. Howard, Scott C — their work on Methotrexate (high-dose), on PubMed (opens in a new tab)7 papers · 836 citesPMID 41134727 (opens PubMed in a new tab)PMID 40075030 (opens PubMed in a new tab)PMID 39254047 (opens PubMed in a new tab)
  2. Perazella, Mark A — their work on Methotrexate (high-dose), on PubMed (opens in a new tab)3 papers · 283 citesPMID 31483318 (opens PubMed in a new tab)PMID 26109096 (opens PubMed in a new tab)PMID 18324877 (opens PubMed in a new tab)
  3. Ramsey, Laura B — their work on Methotrexate (high-dose), on PubMed (opens in a new tab)4 papers · 191 citesPMID 40075030 (opens PubMed in a new tab)PMID 39254047 (opens PubMed in a new tab)PMID 35998099 (opens PubMed in a new tab)
  4. Gupta, Shruti — their work on Methotrexate (high-dose), on PubMed (opens in a new tab)2 papers · 79 citesPMID 39760780 (opens PubMed in a new tab)PMID 35190107 (opens PubMed in a new tab)
  5. Heldrup, Jesper — their work on Methotrexate (high-dose), on PubMed (opens in a new tab)3 papers · 183 citesPMID 40075030 (opens PubMed in a new tab)PMID 35998099 (opens PubMed in a new tab)PMID 29079637 (opens PubMed in a new tab)

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 182 clinical records among the 300 most-relevant of 1,332 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.